Intra-Cellular Therapies, Inc. or PTC Therapeutics, Inc.: Who Invests More in Innovation?

Biotech Giants' R&D Race: Who Leads in Innovation?

__timestampIntra-Cellular Therapies, Inc.PTC Therapeutics, Inc.
Wednesday, January 1, 20142122634579838000
Thursday, January 1, 201587718074121816000
Friday, January 1, 201693831530117633000
Sunday, January 1, 201779419009117456000
Monday, January 1, 2018132166913171984000
Tuesday, January 1, 201989124838257452000
Wednesday, January 1, 202065782137477643000
Friday, January 1, 202188845513540684000
Saturday, January 1, 2022134715000651496000
Sunday, January 1, 2023180142000666563000
Loading chart...

In pursuit of knowledge

Investing in Innovation: A Tale of Two Biotech Giants

In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Intra-Cellular Therapies, Inc. and PTC Therapeutics, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) to bring groundbreaking therapies to market. From 2014 to 2023, PTC Therapeutics consistently outpaced Intra-Cellular Therapies in R&D spending, with an average annual investment nearly three times higher. In 2023, PTC Therapeutics allocated approximately $667 million to R&D, a 735% increase from 2014, showcasing their commitment to innovation. Meanwhile, Intra-Cellular Therapies increased their R&D spending by 748% over the same period, reaching around $180 million in 2023. This strategic focus on R&D underscores the importance of innovation in driving growth and maintaining a competitive edge in the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025